CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Sintilimab Combined with AVD for the treatment of Composite Hodgkin Lymphoma and Follicular Lymphoma: A Case Report and Literature Review
Provisionally accepted
Huami Ye1*
Linlin Huang2- 1Department of Hematology, The Second People's Hospital of Yibin City, Yibin, China
- 2Sichuan Kingmed Center for Clinical Laboratory Co Ltd, Chengdu, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Composite lymphoma have been rarely reported due to their low incidence.The treatment of composite lymphoma depends on the specific lymphoma subtypes involved.no standardized therapeutic regimen has been established. We tried to treat the patient with Sintilimab+AVD for composite Hodgkin lymphoma and follicular lymphoma,after which the patient was able to maintain a normal quality of life and achieved partial remission (PR) .To the best of our knowledge, this is the first attempt to use of PD-1 inhibitor combined with the AVD regimen successfully for the treatment of composite Hodgkin lymphoma and follicular lymphoma.
Keywords: Composite Lymphoma, Hodgkin lymphoma, follicular lymphoma, PD-1 inhibitors, Treatment
Received: 26 Aug 2025; Accepted: 17 Dec 2025.
Copyright: © 2025 Ye and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Huami Ye
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.